Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Tandem Diabetes Care (TNDM) Accumulated Depreciation & Amortization (2016 - 2025)

Tandem Diabetes Care filings provide 13 years of Accumulated Depreciation & Amortization readings, the most recent being $17.7 million for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 6.38% to $17.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.7 million, a 6.38% increase, with the full-year FY2025 number at $17.7 million, up 6.38% from a year prior.
  • Accumulated Depreciation & Amortization hit $17.7 million in Q4 2025 for Tandem Diabetes Care, up from $16.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $17.7 million in Q4 2025 to a low of $13.8 million in Q4 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $15.7 million (2023), compared with a mean of $15.6 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: surged 32.48% in 2021 and later rose 3.5% in 2022.
  • Tandem Diabetes Care's Accumulated Depreciation & Amortization stood at $13.8 million in 2021, then grew by 3.5% to $14.3 million in 2022, then rose by 9.67% to $15.7 million in 2023, then increased by 5.68% to $16.6 million in 2024, then rose by 6.38% to $17.7 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $17.7 million (Q4 2025), $16.6 million (Q4 2024), and $15.7 million (Q4 2023) per Business Quant data.